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Abstract
Background: Type II DNA topoisomerases (topos) are essential enzymes needed for the resolution of topological problems
that occur during DNA metabolic processes. Topos carry out an ATP-dependent strand passage reaction whereby one
double helix is passed through a transient break in another. Humans have two topoII isoforms, a and b, which while
enzymatically similar are differentially expressed and regulated, and are thought to have different cellular roles. The C-
terminal domain (CTD) of the enzyme has the most diversity, and has been implicated in regulation. We sought to
investigate the impact of the CTD domain on activity.
Methodology/Principle Findings: We have investigated the role of the human topoII C-terminal domain by creating
constructs encoding C-terminally truncated recombinant topoIIa and b and topoIIa+b-tail and topoIIb+a-tail chimeric
proteins. We then investigated function in vivo in a yeast system, and in vitro in activity assays. We find that the C-terminal
domain of human topoII isoforms is needed for in vivo function of the enzyme, but not needed for cleavage activity. C-
terminally truncated enzymes had similar strand passage activity to full length enzymes, but the presence of the opposite C-
terminal domain had a large effect, with the topoIIa-CTD increasing activity, and the topoIIb-CTD decreasing activity.
Conclusions/Significance: In vivo complementation data show that the topoIIa C-terminal domain is needed for growth,
but the topoIIb isoform is able to support low levels of growth without a C-terminal domain. This may indicate that topoIIb
has an additional localisation signal. In vitro data suggest that, while the lack of any C-terminal domain has little effect on
activity, the presence of either the topoIIa or b C-terminal domain can affect strand passage activity. Data indicates that the
topoIIb-CTD may be a negative regulator. This is the first report of in vitro data with chimeric human topoIIs.
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Introduction
Type II DNA topoisomerases (topos II) are essential enzymes
that resolve topological problems with DNA that arise during
processes such as DNA replication and transcription, and
chromosome segregation. Their mechanism involves the passing
of one DNA duplex through a transient covalent break in a second
duplex, in an ATP-dependent reaction. Humans have two
topoisomerase II isoforms, a and b, which, while similar, have
distinct patterns of expression and are thought to have different
cellular roles [1]. Human topoIIa is thought to be the isoform
primarily involved with DNA replication and chromosome
segregation, while human topoIIb has recently been implicated
in transcriptional regulation [2–4].
While topoII isoforms show a high degree of sequence
homology, approximately 70% between human topoII a and b,
this is mainly in the N-terminal three-quarters of the protein
sequence where the two catalytic centres are located. The C-
terminal quarter of the protein, while always highly charged,
shows much more sequence diversity. The C-terminal domain has
been shown to be vital for cell viability. However, as C-terminal
truncations are active in vitro, the essential nature of the C-terminal
domain is thought to be linked to regulation [5].
Phosphorylation is a major form of regulation of human topoIIs,
and has been shown to affect activity. Most modification sites are
in the C-terminal domain, although a modification site at human
topoIIa residue S29 that is a substrate for protein kinase C has also
been identified [6]. Phosphorylation sites have been identified in S.
cerevisiae topoII [7]. Some of these modifications are cell cycle
specific, with modification at S1354, S1357, S1364 and T1366
being increased during mitosis, and modification at positions
T1259, S1273, S1270 and S1267 increasing in G1 [7].
Considering the human enzymes, phosphorylation sites have
been identified in topoIIa, with casein kinase II (CKII) being a
principle kinase. aS1524 was identified as a principle phosphor-
ylation site [8]. Several studies have linked human topoIIa
phosphorylation to events at mitosis, and phosphorylation of
aS1212 has been shown to occur at only at mitosis [9].
Phosphorylation has been suggested to activate topoII for
chromatid segregation in anaphase [10], and CKII mediated
aS1469 phosphorylation has been linked to chromatin condensa-
tion at prophase [11]. Additionally, aT1342 has been proposed to
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this to be phosphorylated throughout the cell cycle [13]. Human
topoisomerase II phosphorylation sites, both cell cycle dependent
and independent, are reviewed in Austin and Marsh, 1998 [5].
Modification by SUMO (small ubiquitin-like modifier) has also
been linked to topoII regulation, with work in S. cerevisiae indicating
that the topoII major modification sites (K1220, K1246/K1247
and K1277/K1278) again lie in the C-terminal domain [14]. In S.
cerevisiae topoII, SUMO modification has been linked to chromo-
some stability, with modified topoII enriched at centromeric
regions [15]. Additionally, topoII was found to be SUMO
modified at metaphase, and was proposed to be essential for
centromeric cohesion [14].
Work with human topo enzymes has shown that SUMO is
rapidly conjugated to topoI, topoIIa and topoIIb in response to
DNA damage [16–17]. Additionally, after exposure to topoisom-
erase II inhibitor ICRF-193 human topoIIb, but not topoIIa was
selectively degraded by the proteasome, an activity that was
abolished when the SUMO conjugating enzyme Ubc9 was
knocked out. This implies that the degradation was linked to
SUMO modification, and that this modification differs between
the topoIIa and topoIIb isoforms [18].
A major regulatory feature found in the C-terminal domains of
topoIIs are nuclear localisation and nuclear export sequences
(NLSs and NESs respectively). Without these signals, the enzyme is
not able to localise to the nucleus, where it is essential during DNA
replication, and cell viability is thus diminished or lost.
Considering the human topoII isoforms, in topoIIa a strong
NLS is found at 1454–1497 [19–20], and consistent with this, a
mutant lacking residues 1490–1492 is unable to locate to the
nucleus [21]. Another moderate NLS has been found in topoIIa at
1259–1296 [20]. In topoIIb nuclear localisation signals have been
found in the C-terminal domain, with two strong NLSs have been
identified at 1522–1548 and 1538–1573, with a weaker sequence
at 1294–1332 [20,22]. Studies with isolated topoIIa and b C-
terminal domains tagged with Yellow Fluorescent Protein showed
that the two were differently localised in the nucleus [23].
In human topoIIa an NES was initially localised to the region
1018–1088 [24], and subsequently this was narrowed down to two
sequences, 1017–1028 and 1054–1066, the latter of which is the
stronger sequence [25]. In topoIIb an NES sequence has been
idenfied between residues 1034–1044 [24].
Work with chimeric ‘tail swap’ proteins, where the C-terminal
domain of topoIIa or topoIIb is joined to the main body of the
enzyme belonging to the opposite isoform, has been reported. A
chimera of murine topoII consisting of the body of topoIIa and the
tail of topoIIb showed that this protein was unable to support
growth [26]. Conversely, a study examining the ability of human
topoII chimeric tail swap proteins to rescue topoIIa cells in vivo
found that the chimeric proteins, particularly those bearing the
topoIIa C-terminal domain, could support growth [27].
To assess whether the C-terminal domain, as the most diverse
part of the protein, impacted the relative activities of topoIIa and
b, we aimed to construct and characterise in vitro and in vivo full
length and C-terminally truncated forms of human topoIIa and b,
and two ‘tail swap’ chimeric proteins where the C-terminal
domain of each isoform is linked to the main sequence of the
opposite isoform. In contrast to a recently published study
describing the in vivo characterisation of tail swap proteins, where
the C-terminal domain boundary was determined by alignment
[27], the constructs described here have boundaries chosen based
on those determined by limited proteolysis [28]. The construction
process, as well as subsequent characterisation, is reported here.
Materials and Methods
Reagents
All chemicals were purchased from Sigma, BDH or Boehringer
Mannheim. Restriction enzymes were purchased from NBL Gene
Sciences Ltd, New England Biolabs, or Pharmacia Biotech. T4
Ligase was purchased from Gibco BRL. Etoposide was a gift from
Prof. H. Newell, NICR, Newcastle, UK. mAMSA, Merbarone
and Suramin were obtained from the Drug Synthesis and
Chemistry branch, NCI, Bethesda, MD. Quercetin, Quercetage-
tin, Myricetin and Baicalein were provided by Prof. L.M. Fisher.
mAMCA, DACA and Cl-DACA were provided by Prof. B
Baguley, Auckland Cancer Society, New Zealand. All other
cytotoxics were purchased from Sigma.
Plasmids and Yeast Strains
S. cerevisiae strain JEL1 was used for overexpression of proteins.
Yeast strain JN394t2-4, a temperaturesensitivestrainthatisviableat
25uC but non-viable at 35u, was used in complementation analysis.
All of the plasmids encoding topoII isoforms express protein
under the control of the GAL1 promoter, and have a URA3
marker gene, the yeast 2m plasmid replication origin and the b-
lactamase gene and replication origin of E. coli pBR322 are also
present. Plasmid YEpWob6, used to express recombinant human
topoIIa, encodes the first 5 amino acids of S. cerevisiae topoII fused
to residues 29–1531 of human topoIIa. Plasmid YEphTOP2b
encodes recombinant human topoIIb with the S165R mutation,
with residues 46–1621 fused to the first 5 amino acids of S. cerevisiae
topoII [29–30]. Plasmid YEphTOP2bKLM encodes recombinant
wild type topoIIb residues 46–1621 (without mutation S165R)
fused to the first 5 of S. cerevisiae topoII. Plasmid intermediates used
in the cloning process to construct C-terminal truncations and tail
swaps are described in the ‘Results’ section and figure legends.
Construction of mutant plasmids
Plasmids encoding truncated topoIIa and topoIIb, as well as two
‘tail swap’ chimeric proteins with the opposite C-terminal domain
fused to the main coding sequence were constructed as described
in ‘Results’. In all cases restriction digests were carried out
according to manufacturer’s instructions. Fragments were sepa-
rated by agarose gel electrophoresis and then purified using a
QIAquick Gel extraction spin column. Ligations were then carried
out using T4 ligase and the manufacturer’s buffers, incubating
with 0.5mM ATP for 16 hours at 4uC.
Tail swap mutants were constructed with triple cloning proce-
dures, then the junction sites were confirmed by sequencing both
strands with dideoxy DNA sequencing using appropriate primers
and a Sequenase version 2.0 DNA sequencing kit (Amersham).
Preparation of protein
Recombinant human topoIIa and b proteins were expressed
and purified as described previously [28,31]. ATP dependent and
independent relaxation assays were done with purified fractions to
identify those free of topoI activity.
In vitro assays
Decatenation assays and cleavage assays with an end-labelled
4.3 kb linear DNA fragment from pBR322 were done as described
previously [29–30].
In vivo assays
Complementation assays were carried out in a temperature
sensitive yeast strain JN394t2-4, and plasmids encoding topoIIa
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or chimeric proteins. Yeast were grown in Ura- selective media at
the permissive temperature (25uC) to an OD600 of 1, and then
serially diluted in sterile microtitre trays. These cultures were then
transferred to plates with an aluminium replicator, then incubated
at the permissive, semi-permissive and non-permissive (25uC,
30uCo r3 5 uC) temperatures respectively on glucose containing
media, then growth was scored.
Results
Construction of plasmids
Truncations at the 39 end of the coding sequence of topoIIa and
topoIIb (S165R) were constructed from plasmids YEpWob6 and
YEphTOP2b respectively. The truncated topoIIa plasmid encodes
residues 29–1242 and the truncated topoIIb plasmid encodes
residues 46–1263, these being the start of the C-terminal domains
as determined by limited proteolysis experiments [28,32,33].
Schematics of these plasmids are shown in Figure 1.
In the construction of C-terminally truncated topoIIa, PCR was
used to introduce a PstI restriction site in the human topoIIa
coding sequence and then to generate the full coding sequence. A
fragment was generated between codon 791 (over a KpnI site) and
codon 1244 (over the PstI site introduced above) of topoIIa. The
PCR product was cloned into a Bluescript plasmid with a XhoI
site immediately 39 to the 792–1242 fragment, then excised by
digestion with KpnI and XhoI. This was then cloned into the
YEpWob6 plasmid, replacing the fragment 792–1531.
In the construction of C-terminally truncated topoIIb, multiple
internal restriction sites in the topoIIb sequence meant that a
complex cloning procedure was necessary. A fragment containing
topoIIb residues 900–1263 was excised and cloned into a
Bluescript plasmid between BamHI and PstI restriction sites, this
having a XhoI site 36 residues downstream of the PstI site. A
fragment between BamHI to the XhoI beginning at codon 900
was excised and cloned into a vector containing topoIIb codons
46–899 plus the YEp backbone.
Plasmids encoding chimeric ‘tail-swap’ proteins were created
using a triple ligation approach and PCR to generate unique sites.
Construction of the topoIIa+b tail plasmid, encoding topoIIa
residues 30–1244 fused to topoIIb residues 1263–1621, is
illustrated in figure 2A. Likewise, construction of the topoIIb
(S165R)+a tail plasmid, encoding topoIIb residues 46–1263 fused
to topoIIa residues 1244–1531, is illustrated in figure 2B.
All topoIIb constructs containing the S165R mutation were
changed to give wild type sequence by site directed mutagenesis
using a Chameleon kit (stratagene) according to manufacturer’s
instructions.
TopoII protein activities
The decatenation activity of wild type topoIIa, C-terminally
truncated topoIIa, and topoIIa+b tail was assayed. The values for
50% decatenation (D50), in ng of protein, are shown in figure 3A.
There is no significant difference in D50 between topoIIa and its
C-terminal truncation, with values of 4.561.3 and 661n go f
protein respectively. The topoIIa+b tail chimera however does
show a significant reduction in decatenation as compared to full
length topoIIa, with a D50 of 2961 (p=0.0008 in a two-tailed
unpaired student t-test). This implies that while topoIIa can
function perfectly well without a C-terminal domain, the b-tail on
the topoIIa enzyme impedes activity.
It is possible that the observed reduction in catalytic activity
seen with the topoIIa+b tail chimeric protein was an artefact,
caused by the insertion of the tail into the enzyme altering a
property such as conformation. A chimeric protein of topoIIb
mutant S165R, known to give a 5-fold reduction in decatenation
activity [34], fused to the a-tail, was used to address this concern. If
the insertion of the tail per se impedes catalytic activity, then the
topoIIb (S165R)+a tail would be expected to have still lower
decatenation activity than topoIIb(S165R). As shown in figure 3A
the presence of the a tail gave no reduction in the decatenation
activity of topoIIb(S165R). As with topoIIa, removing the topoIIb
C-terminal domain gave no significant difference in activity, with
D50 values of 5068 and 6068 ng protein for topoIIb(S165R) and
C-terminally truncated topoIIb(S165R) respectively. The activity
of the topoIIb(S165R)+a tail chimera was increased very slightly
with a D50 of 41.560.5 ng protein, however this difference was
not statistically significant (p=0.4001, figure 3A).
Complementation analysis of isoforms
To assess the in vivo functional activity of the truncated and
chimeric proteins, complementation experiments were carried out
in the temperature sensitive yeast strain JN394t2-4. Data are
shown in table 1. All of the topoIIb (S165R) plasmids were unable
to complement at the restrictive temperature, consistent with
previous results [34]. Both wild type topoII isoforms supported
good growth as expected. The truncated topoIIa and topoIIa+b
tail proteins were unable to complement, but interestingly the
truncated topoIIb and topoIIb+a tail proteins were able to support
low levels of growth.
Figure 1. Schematic of C-terminally truncated topoIIa and
topoIIb constructs. Shown are the topoII sequence boundaries, the
GAL1 promoter, the 2m replication origin, the URA3 marker gene, and
an ampicillin resistance gene. Restriction sites used in plasmid
construction are indicated.
doi:10.1371/journal.pone.0001754.g001
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The cleavage activity of each of the wild type and C-terminal
truncation mutant proteins was assessed in an end-labelled
cleavage assay, in the presence and absence of drug. While the
topoIIb proteins here had mutation S165R this has been shown to
have no effect on cleavage under the conditions used [34]. In the
absence of drug all six proteins gave cleavage at similar sites (data
not shown). While topoIIa gave cleavage at more sites than
topoIIb this difference wasn’t statistically significant. The same
pattern was seen with the truncated and tail swap proteins, with
topoIIa proteins generally giving slightly more cleavage than their
topoIIb counterpart, however this difference wasn’t significant.
Drug stimulated cleavage was assayed with flavonoids quercetin,
quercetagetin, myricetin, and baicalein, acridines mAMSA and
mAMCA, etoposide and mitoxantrone. No difference in cleavage
pattern between proteins was seen with drugs with the exception of
truncated topoIIb which promoted cleavage with mAMCA sites
corresponding to a combination of topoIIb and topoIIa.
Additionally truncated topoIIb promoted no cleavage with
mitoxantrone (figure 3B), and topoIIa+b tail promoted cleavage
with quercetagetin at sites more in common with topoIIb than
topoIIa. This indicates that the C-terminal domain of topoIIb has
a role in the determination of cleavage sites with certain drugs.
Discussion
Human topoII isoforms a and b, while enzymatically similar in
vitro, have been shown to have different cellular roles. While
topoIIa is thought to be the isoform primarily responsible for DNA
segregation, topoIIb has recently been linked to transcription
initiation [2–4]. Here we report the construction and character-
isation of recombinant truncated and tail swap chimeric proteins.
Figure 2. Construction of chimeric ‘tail-swap’ plasmids. A–construction of topoIIa+b tail. TopoIIa fragments 30–791 and 792–1244 and topoIIb
fragment 1263–1621 were generated using restriction digests as shown, then ligated to give the final construct shown. B–construction of topoIIb+a
tail. TopoIIb fragments 46–899 and 900–1263 and topoIIa fragment 1244–1531 were generated with restriction digests as indicated, then ligated to
give the final construct shown [32].
doi:10.1371/journal.pone.0001754.g002
Figure 3. Activity of recombinant proteins. A: Decatenation activity of all proteins, each column is the mean of at least two independent
experiments. Standard errors are shown, with significant difference from full length enzyme marker with ‘***’. B: Representative cleavage experiment
with 4.3 kb linearised pBR322 DNA with all proteins in the presence of mitoxantrone. TopoIIb proteins in this case carry the S165R mutation.
doi:10.1371/journal.pone.0001754.g003
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point of truncation in this case was chosen to align with a viral
topoII lacking the C-terminal domain [35]. C-terminal truncations
of topoIIa and b reported here were based on domain organisation
as determined by the cleavage sites in limited proteolysis studies
[28]. Likewise, human chimeric tail swap proteins have been
described and their in vivo function reported, but these also had
domain boundaries based on alignment rather than proteolysis
sites [27]. Here we report, for the first time, the creation of C-
terminally truncated recombinant human topoII proteins based on
domain structure indicated by limited proteolysis experiments.
Furthermore, we have also created chimeric recombinant human
topoII tail swap proteins based on this definition of the C-terminal
domain. Additionally, this manuscript is the first report of
characterisation of the in vitro function of human chimeric tail
swap proteins.
Complementation analysis showed, as previously reported, that
the S165R mutant proteins were not functional in vivo [34]. The
topoIIa C-terminal truncation couldn’t support growth, in
accordance with previous work showing that the loss of the C-
terminal domain, and the localisation signals within it, are
detrimental to growth [26,36]. The topoIIa+b chimera was also
unable to support growth suggesting that the b C-terminal domain
is unable to restore the localisation of the enzyme, or perhaps that
the topoIIb C-terminal domain has a different function to the
topoIIa C-terminal domain. This would be consistent with
previous experiments showing that human topoIIa preferentially
relaxes positive supercoils, whereas topoIIb showed no preference
[37]. This result is in contrast to a study with a murine topoIIa+b
protein which was able to support growth in S. cerevisiae strain
NAY113 [26]. This difference could be species specific, or due to
differences in the definition of the start of the C-terminal domain.
In the murine study the last 444 amino acids of the b-tail were
used to replace the equivalent region on topoIIa, in contrast to 358
residues here, with 356 amino acids of the topoIIa tail lost in the
murine chimera in contrast to 289 here.
Perhaps more surprising is that topoIIb truncated protein and
topoIIb+a tail protein can support low levels of growth, implying
that some localisation to the nucleus is still present. Known nuclear
localisation signals are shown in figure 4 and, with the exception of
S. pombe topoII which also has an N-terminal signal, all sequences
are found in the C-terminal domain [20,22,38,39]. It is therefore
unclear why the truncated topoIIb protein is able to support low
levels of growth (and hence localise, albeit inefficiently, to the
nucleus), but it is possible that this is due to a presently unknown
mechanism, perhaps linked to topoIIb specific modification, or an
unidentified NLS specific to topoIIb. This would be consistent
with previous work that showed that the topoIIa and b C-terminal
domains were differently localised [23].
A previous study into human chimeric enzymes found that
proliferation of topoIIa knockout human cells was supported
in all cases by enzymes bearing the topoIIa C-terminal
domain, but that proliferation was only supported rarely and
when protein was expressed in large quantities for enzymes
bearing the topoIIb C-terminal domain. The relative levels of
growth support are consistent with the data presented here (where
the topoIIa C-terminal domain chimera supports low levels of
growth and the topoIIb C-terminal domain chimera supports no
growth at all), although the levels of growth differ, perhaps because
of differences in the experimental systems or the sensitivity of
methods [27].
The decatenation data imply that the topoII C-terminal domain
is involved in the modulation of catalytic activity in the two human
isoforms. The truncated topoII proteins had no difference in in vitro
decatenation activity as compared to their full length counterparts
suggesting that the C-terminal domain is not necessary for in vitro
activity, which is consistent with previous data [26,40,41]. While
the absence of the C-terminal domain for topoIIa or b had no
effect on strand passage activity, the presence of the C-terminal
domain from the opposite isoform had a noticeable effect with a
clear trend emerging. The presence of the b-tail on the topoIIa
isoform core gave a statistically significant decrease in strand
passage activity compared to the native topoIIa protein, and the
presence of the a-tail on the topoIIb isoform core gave an increase
in activity compared to the native topoIIb protein, although this
time not significant, towards that of the native topoIIa protein. As
the truncated forms of each protein had no difference in activity
when compared to the full length, this implies that it is the
presence of the a or b tail that is important for the level of strand
passage, acting as a regulator. In this case of the topoIIb C-
terminal domain particularly, this regulation (negative in this case),
is quite striking. While it can’t formally be excluded that the
reduced activity of the chimeric topoIIa+b tail protein is due to the
tail swap process, this seems unlikely, as if the process itself reduced
activity this should also be seen with the topoIIb(S165R)+a tail
protein. In fact the opposite is seen, with the absence of the b-
CTD seeming to ‘release’ the enzyme activity a little and increase
the rate of decatenation.
The regulation of catalytic activity by the C-terminal domain
could be mediated via differential modification, for instance
phosphorylation or SUMOylation, or could be linked to the
extensive differences in primary sequence between the two C-
terminal domains.
Observations reported previously support the hypothesis that
topoIIa and b C-terminal domains are important in differential
regulation of the isoforms. All of the SUMO modification sites
identified to date have been located in the C-terminal domain of
topoII [14]. SUMO conjugation to topoI, topoIIa and topoIIb has
also been linked to the human cellular response to DNA damage
[16–17]. However, differential degradation of topoIIb but not
topoIIa was observed in response to treatment with ICRF-193,
strongly suggesting that the two isoforms are regulated differently
by SUMO modification [18].
An analysis of the theoretical protein parameters of full length
and truncated topoIIa and topoIIb, and their tail swap derivatives,
is shown in table 2. What is immediately obvious is that, while the
full length and truncated topoII isoforms all have similar
Table 1. Complementation of topoII isoforms
25uC3 0 uC3 5 uC
TopoIIa ++ ++ ++
TopoIIa truncated +++ +++ -
TopoIIa+b tail ++ ++ -
TopoIIb ++ ++ ++
TopoIIb(S165R) ++ ++ -
TopoIIb truncated ++ ++ +/2
TopoIIb(S165R)
truncated
++ + -
TopoIIb+a tail ++ ++ +/2
TopoIIb(S165R)+a tail ++ ++ -
-n og r o w t h ,+/2 poor growth,+some growth, ++ good growth, +++ excellent
growth
All experiments were repeated at least twice.
doi:10.1371/journal.pone.0001754.t001
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theoretical pI, the theoretical pI of the isolated C-terminal domain
of topoIIb is considerably lower than other topoII proteins. This is
linked to the higher number of acidic residues compared to basic
residues seen with this fragment. Unsurprisingly, the a+b tail
protein has a lower theoretical pI than full length topoIIa, and the
b+a tail protein has a higher theoretical pI than the full length
topoIIb protein, but a similar pI to the truncated topoIIb protein
[42]. It would thus appear that the lower theoretical pI of the b-
CTD acts to lower the pI of the core protein to which it is
attached. Conversely, the addition of the a-CTD has little effect on
either core protein’s theoretical pI.
Cleavage data suggests that the C-terminal domain is not
generally involved in cleavage, although there was a consistent, yet
non-significant, increase in cleavage with the topoIIa derived
proteins. Most drugs showed no difference in drug-stimulated
cleavage patterns between topoIIa and b, implying that the C-
terminal domain has no impact on the action of these drugs,
consistent with previous work showing that topoIIa and topoIIb
cleave at similar sites [43]. There were exceptions to this rule
however, for example the truncated topoIIb showed no cleavage
with mitoxantrone, showing that some drugs may have specific
interactions that involve the C-terminal domain of human
topoIIb.
In summary, we report the construction of C-terminally
truncated and chimeric human topoII enzymes, and show that
the C-terminal domain impacts on the activity of the two human
isoforms. Further characterisation of human topoIIa and topoIIb,
perhaps by investigating the effect of SUMOylation on either
isoform, or the cellular localisation of these tail swap proteins, will
be needed to elucidate their different interactions with DNA
substrates and functional roles in cells.
Figure 4. Schematic showing the position of the C-terminal domain of type II topoisomerases. Above each bar are the residue numbers
at the start and end of the primary sequence, plus the point equating to the start of the C-terminal domain (indicated by arrows), as determined by
limited proteolysis where known, and by alignment with this point where this is not known. Also shown are active site tyrosines (Y), known nuclear
localisation sequences (NLS-dark grey) and known nuclear export sequences (NES–light grey). NLS sequences have been identified in human topoIIa
(1259–1296, 1454–1497 [20]), human topoIIb (1294–1332, 1522–1548, 1538–1573 [20]), S. cerevisiae topoII (1227–1242 [38]) and S. pombe (26–44,
1227–1242, 1322–1339, 1335–1357 [39]). NES sequences have been identified in human topoIIa (1017–1028, 1054–1066 [24]) and human topoIIb
(1034–1044 [24]).
doi:10.1371/journal.pone.0001754.g004
Table 2. Protein parameters for human topoII isoforms
Amino acids Theoretical pI Acidic amino acids Basic amino acids
TopoIIa 1–1531 8.82 226 (14%) 246 (16%)
TopoIIb 1–1621 8.22 243 (15%) 250 (15%)
Truncated topoIIa 1–1242 8.71 173 (14%) 187 (15%)
Truncated topoIIb 1–1263 8.83 163 (13%) 185 (15%)
a CTD 1243–1531 9.09 53 (18%) 59 (20%)
b CTD 1264–1621 5.04 77 (22%) 65 (18%)
TopoIIa +b tail 1–1600 7.69 250 (16%) 252 (16%)
TopoIIb+a tail 1–1552 8.9 219 (14%) 244 (16%)
Shown are the residues of the protein, the theoretical pI and number of acidic (negatively charged, D,E) and basic (positively charged, R,K) amino acids. Shown in
parentheses is the percentage of amino acids with each charge in each protein. Reproduced and modified from KL Gilroy, thesis [42].
doi:10.1371/journal.pone.0001754.t002
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